We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-a... read more Featured Products: More products

Download Mobile App





Co-Diagnostics Showcases PCR Platform at WHX Labs Dubai

By LabMedica International staff writers
Posted on 10 Feb 2026

Co-Diagnostics, Inc. More...

(Co-Dx; Salt Lake City, UT, USA), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is showcasing its transformative PCR platform at WHX Labs Dubai, taking place February 10–13, 2026.

Co-Dx's participation at the event follows the formation of its recently announced joint venture, CoMira Diagnostics, with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia. CoMira Diagnostics was formed to localize manufacturing and distribution of Co-Diagnostics' technologies and intellectual property across Saudi Arabia and 18 additional countries in the Middle East and North Africa ("MENA"). The event provides an opportunity for Co-Dx to engage with regional stakeholders and support its strategy to expand access to high-quality molecular diagnostics throughout the region, including the company's upcoming Co-Dx PCR platform, currently in clinical studies in the United States.

Attendees interested in learning more about the Co-Dx's products can visit Co-Dx and CoMira representatives at the World Trade Center Utah booth. World Trade Center Utah is a member of the World Trade Centers Association founded in 2006 with the goal of helping Utah companies increase revenue and create jobs by expanding international sales, attracting foreign investment, and facilitating international partnerships.

The Co-Dx PCR platform is a portable, real-time molecular diagnostics system designed to bridge the gap between high-quality laboratory testing and the convenience of at-home or point-of-care (PoC) settings. The platform aims to democratize access to "gold-standard" PCR technology by making it compact, affordable, and user-friendly. It delivers clinical-grade results in approximately 30 minutes, providing a rapid turnaround that eliminates the need for centralized laboratory processing. The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, all associated tests and licensed applications of the technology) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

Related Links:
Co-Diagnostics, Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Urinalysis Solution
UN-9000
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.